Skip to content
Screener
Q2 '26Q1 '26Q4 '25Q3 '25Q2 '25
-$56.62M-112%-$19.86M+17.5%-$33.76M-69.0%-$26.93M-53.5%-$26.73M-47.5%
$212K-15.9%$227K-7.0%$265K+1.9%$256K+16.9%$252K+21.2%
$7.2M+64.1%$6.96M+72.4%$5.69M+77.4%$4.74M+48.8%$4.39M+86.4%
-$41.46M-65.4%-$13.06M+35.5%-$24.7M-71.0%-$17.47M-6.4%-$25.07M-53.3%
$78K+255%$86K-70.4%$169K-25.2%$134K-4.3%$22K-97.7%
$25.6M+13.3%$37.94M+80.4%-$174.32M-$56.78M-7.0%$22.6M+121%
$1.41M+2,340%$531K+10,520%$311K+4,343%$270.53M-$63K-100%
$25.41M+3,080%-$198.71M$196.29M+377%-$2.54M-107%
-$41.53M-65.5%-$13.15M+36.0%-$24.87M-69.5%-$17.6M-6.3%-$25.09M-44.9%

FAQ

How much cash does Rapport Therapeutics, Inc. generate?
Rapport Therapeutics, Inc. (RAPP) generated -$96.7M in operating cash flow over the trailing twelve months.
What is Rapport Therapeutics, Inc.'s free cash flow?
After $467.0K of capital expenditures, Rapport Therapeutics, Inc.'s free cash flow was -$97.1M over the trailing twelve months, down 26.4% year over year.
Where does Rapport Therapeutics, Inc.'s cash flow data come from?
Every line is extracted from Rapport Therapeutics, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.